Immunohistochemical markers in the evaluation of tumors of the urinary bladder: A review

Analytical and Quantitative Cytology and Histology

Volumn 27, Issue 6, 2005, Pages 301-316

  Emerson, Robert E ^a,b   Cheng, Liang ^a,b,c  

^a INDIANA UNIVERSITY   (United States)

^b Department of Pathology and Laboratory Medicine ^*  (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Bladder neoplasms; Immunohistochemistry; Metastasis

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; PACLITAXEL; TRASTUZUMAB;

BLADDER CARCINOMA; BLADDER TUMOR; CANCER CHEMOTHERAPY; DIAGNOSTIC VALUE; DRUG RESPONSE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TECHNOLOGY; UROGENITAL TRACT TUMOR;

CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 29144504996     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88:625-631
2. Cheng L, Cheville JC, Neumann RM, Bostwick DG: Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-447
3. Cheng L, Cheville JC, Leibovich BC, Weaver AL, Egan KS, Spotts BE, Neumann RM, Bostwick DG: Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-2474
4. Harnden P, Eardley I, Joyce AD, Southgate J: Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870-875
5. Mallofre C, Castillo M, Morente V, Sole M: Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 2003;16:187-191
6. McKenney JK, Desai S, Cohen C, Amin MB: Discriminatory immunohistochemical staining of urothelial carcinoma in situ an non-neoplastic urothelium. Am J Surg Pathol 2001;25:1074-1078
7. Harnden P, Mahmood N, Southgate J3A Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999;353:974-977
8. Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Nehra A, Malek RS, Zincke H, Bostwick DG: Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. Cancer 2000;88:1679-1686
9. Parker DC, Folpe A, Bell J, Oliva E, Young RH, Cohen C, Amin MB: Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27:1-10
10. Kaufmann O, Volmerig J, Dietel M: Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinoma. Am J Clin Pathol 2000;113:683-687
11. Moll R, Wu X-R, Lin J-H, Sun T-T. Uroplakins, specific membrane proteins if urothelial umbrella cells, as histological markers of metastatic transitional cell carcinoma. Am J Pathol. 1995;147:1383-1397.
12. Ramani P, Birch BRP, Harland SJ, Parkinson MC: Evaluation of endothelial markers in detecting blood and lymphatic channel invasion in pT1 transitional cell carcinoma of the bladder. Histopathology 1991;19:551-554
13. Yang XJ, Lecksell K, Epstein JI: Can immunohistochemistry enhance the detection of micrometastases in pelvic lymph nodes from patients with high-grade urothelial carcinoma of the bladder? Am J Clin Pathol 1999;112:649-653
14. Jiang J, Ulbright TM, Younger C, Sanchez K, Bostwick DG, Koch MO, Eble JN, Cheng L: Cytokeratin 7 and 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med 2001;125:921-923
15. Lin O, Cardillo M, Dalbagni G, Linkov I, Hutchinson B, Reuter VE: Nested variant of urothelial carcinoma: A clinicopathologic and immunohistochemical study of 12 cases. Mod Pathol 2003;16:1289-1298
16. Volmar KE, Chan TY, De Marzo AM, Epstein JI: Florid von Brunn nests mimicking urothelial carcinoma: A morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma. Am J Surg Pathol 2003;27:1243-1252
17. Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V: Pathogenesis of invasive micropapillary carcinoma: Role of MUC1 glycoprotein. Mod Pathol 2004;19:1045-1050
18. Samaratunga H, Khoo K: Micropapillary variant of urothelial carcinoma of the urinary bladder: A clinicopathological and immunohistochemical study. Histopathology 2004;45:55-64
19. Oyasu R, Nan L, Smith P, Kawamata H: Human chorionic gonadotropin beta-subunit synthesis by undifferentiated urothelial carcinoma with syncytiotrophoblastic differentiation. Arch Pathol Lab Med 1994;118:715-717
20. Grammatico D, Grignon DJ, Eberwein P, Shepherd RR, Hearn SA, Walton JC: Transitional cell carcinoma of the renal pelvis with choriocarcinomatous differentiation: Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. Cancer 1993;71:1835-1841
21. Serio G, Zampatti C, Ceppi M: Spindle and giant cell carcinoma of the urinary bladder: A clinicopathological, light microscopic and immunohistochemical study. Br J Urol 1995;75:167-172
22. Torenbeek R, Blomjous CEM, de Bruin PC, Newling DWW, Meijer CJLM: Sarcomatoid carcinoma of the urinary bladder: Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol 1994;18:241-249
23. Perret L, Chaubert P, Hessler D, Guillou L: Primary heterologous carcinosarcoma (metaplastic carcinoma) of the urinary bladder: A clinicopathologic, immunohistochemical, and ultrastrucrural analysis of eight cases and a review of the literature. Cancer 1998;82:1535-1549
24. Lopez-Beltran A, Luque RJ, Vicioso L, Anglada F, Requena MJ, Quintero A, Montironi R: Lymphoepithelioma-like carcinoma of the urinary bladder: A clinicopathologic study of 13 cases. Virchows Arch 2001;438:552-557
25. Gulley ML, Amin MB, Nicholls JM, Banks PM, Ayala AG, Srigley JR, Eagan PA, Ro JY: Epstein-Barr virus is detected in undifferentiated nasopharyngeal carcinoma but not in lymphoepithelioma-like carcinoma of the urinary bladder. Hum Pathol 1995;26:1207-1214
26. Dahm P, Gschwend JE: Malignant non-urothelial neoplasms of the urinary bladder: A review. Eur Urol 2003;44:672-681
27. Grignon D, Ro J, Ayala A, Johnson D, Ordonez N: Primary adenocarcinoma of the urinary bladder: A clinicopathologic analysis of 72 cases. Cancer 1990;67:2165-2172
28. Werling RW, Yaziji H, Bacchi CE, Gown AM: CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-310
29. Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL: The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-1399
30. Tamboli P, Mohsin SK, Hailemariam S, Amin MB: Colonic adenocarcinoma metastatic to the urinary tract versus primary tumors of the urinary tract with glandular differentiation: A report of 7 cases and investigation using a limited immunohistochemical panel. Arch Pathol Lab Med 2002;126:1057-1063
31. Wang HL, Lu DW, Yerian LM, Alsikafi N, Steinberg G, Hart J, Yang XJ: Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001;25:1380-1387
32. Oliva E, Amin MB, Jimenez R, Young RH: Clear cell carcinoma of the urinary bladder: A report and comparison of four tumors with Mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems. Am J Surg Pathol 2002;26:190-197
33. Drew P, Murphy WM, Civantos F, Speights VO: The histogenesis of clear cell adenocarcinoma of the lower urinary tract: Case series and review of the literature. Hum Pathol 1996;27:248-252
34. Gilcrease MZ, Delgado R, Vuitch F, Albores-Savvedra J: Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: A histopathologic and immunohistochemical comparison. Hum Pathol 1998;29:1451-1456
35. Cheng L, Cheville JC, Sebo TJ, Eble JN, Bostwick DG: Atypical nephrogenic metaplasia of the urinary tract: A precursor lesion? Cancer 2000;88:853-861
36. Lopez-Beltran A, Luque RJ, Quintero A, Requena MJ, Montironi R: Hepatoid adenocarcinoma of the urinary bladder. Virchows Arch 2003;442:381-387
37. Cheng L, Pan C, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova M, Nigro K, Koch MO, Eble JN: Small cell carcinoma of the urinary bladder: A clinicopathologic analysis of 64 patients. Cancer 2004;101:957-962
38. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, Koch MO, Zhang S, Pan C-X, Baldridge LA: Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005;166:1533-1539
39. Soriano P, Navarro S, Gil M, Llombart-Bosch A: Small-cell carcinoma of the urinary bladder: A clinicopathological study of ten cases. Virchows Arch 2004;445:292-297
40. Iczkowski KA, Shanks JH, Bostwick DG: Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma. Histopathology 1998;32:322-327
41. Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis CG, Collins TR, Wetherington RW, Bostwick DG: Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Histopathology 1999;35:150-156
42. Jones TD, Kernek KM, Yang X, Lopez-Beltran A, MacLennan GT, Eble JN, Lin H, Pan C, Tretiakova M, Baldridge LA, Cheng L: Thyroid transcription factor-1 expression in small cell carcinoma if the urinary bladder: An immunohistochemical profile of 44 cases. Hum Pathol (in press)
43. Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL: Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 2000;13:238-242
44. Cheuk W, Kwan MY, Suster S, Chan JKC: Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids in the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med 2001;125:228-231
45. Wang X, Jones TD, MacLennan GT, Yang XJ, Lopez-Beltran A, Eble J, Lin H, Baldridge LA, Tretiakova M, Cheng L: p53 Expression in small cell carcinoma of the urinary bladder. Anticancer Res (in press)
46. Pan C-X, Yang X, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, Jones TD, Lin H, Nigro K, Papavero V, Tretiakova M, Cheng L: C-kit expression in small cell carcinoma of the urinary bladder: Prognostic and therapeutic implications. Mod Pathol 2005;18:320-323
47. Cheng L, Leibovich B, Cheville J, Ramnani D, Sebo T, Neumann R, Nascimento A, Zincke H, Bostwick D: Paraganglioma of the urinary bladder: Can biologic potential be predicted? Cancer 2000;88:844-852
48. Kruger S, Schmidt H, Kausch I, Bohle A, Holzhausen HJ, Johannisson R, Feller AC: Primitive neuroectodermal tumor (PNET) of the urinary bladder. Pathol Res Pract 2003;199:751-754
49. Sugihara A, Kajio K, Yoshimoto T, Tsujimura T, Iwasaki H, Yamada N, Terada N, Tsuji M, Nojima M, Yabumoto H, Mori Y, Shima H: Primary carcinoid tumor of the urinary bladder. Int Urol Nephrol 2002;33:53-57
50. Torenbeek R, Lagendijk JH, van Diest PJ, Bril H, van de Mollengraft FJM, Meijer CJ: Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology 1998;32:20-27
51. Epstein JI, Kuhajda FP, Liberman PH: Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol 1986;17:939-942
52. Genega EM, Hutchinson B, Reuter VE, Gaudin PB: Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol 2000;13:1186-1191
53. Varma M, Morgan M, Amin MB, Wozniak S, Jasani B: High molecular weight cytokeratin antibody (clone 34betaE12): A sensitive marker for differentiation of high-grade invasive urothelial carcinoma from prostate cancer. Histopathology 2003;42:167-172
54. Pantuck AJ, Murphy DP, Amenta PS, Das KM, Cummings KB, Weiss RE: The monoclonal antibody 7E12H12 can differentiate primary adenocarcinoma of the bladder and prostate. Br J Urol 1998;82:426-430
55. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG: Expression of a-methylacyl-CoA racemase (P504S) in various tissues: A study of 761 cases. Hum Pathol 2003;34:792-796
56. Torbenson M, Dhir R, Nangia A, Becich MJ, Kapadia SB: Prostatic carcinoma with signet ring cells: A clinicopathologic and immunohistochemical analysis of 12 cases, with review of the literature. Mod Pathol 1998;11:552-559
57. Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R: P63 immunoreactivity distinguishes upper urinary tract transitional cell carcinoma and renal cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem 2003;51:1097-1099
58. Sim SJ, Ro JY, Ordonez NG, Park YW, Kee KH, Ayala AG: Metastatic renal cell carcinoma to the bladder: A clinicopathologic and immunohistochemical study. Mod Pathol 1999;12:351-355
59. Chu P, Arber DA: Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Am J Clin Pathol 2000;113:374-382
60. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L: OCT4 is a sensitive and specific marker for testicular seminoma and embryonal carcinoma. Am J Surg Pathol 2004;28:935-940
61. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 2003;63:2244-2250
62. Cheng L: Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004;101:2006-2010
63. Hattab EM, Tu PH, Wilson JD, Cheng L: OCT4 immunohistochemistry is superior to placental alkaline phosphatase (FLAP) in the diagnosis of central nervous system germinoma. Am J Surg Pathol 2005;29:368-371
64. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FW: OCT4: A novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol 2004;28:1341-1346
65. Ormsby AH, Haskell R, Jones D, Goldblum JR: Primary seminal vesicle carcinoma: An immunohistochemical analysis of four cases. Mod Pathol 2000;13:46-51
66. Moskaluk CA, Zhang H, Powell SM, Cerilli L, Hampton GM, Frierson HF: Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-919
67. Chu P, Wu E, Weiss LM: Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000;13:962-972
68. Wang NP, Zee S, Zarbo RJ, Bacchi C, Gown AM: Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem 1995;3:99-107
69. Moll R, Lowe A, Laufer J, Franke WW: Cytokeratin 20 in human carcinomas: A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-447
70. Xu X, Sun T-T, Gupta PK, Zhang P, Nasuti JF: Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer (Cancer Cytopathol) 2001;93:216-221
71. Logani S, Oliva E, Amin MB, Folpe AL, Cohen C, Young RH: Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: Histogenetic and diagnostic implications. Am J Surg Pathol 2003;27:1434-1441
72. Ordonez NG: Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology 2000;36:433-438
73. Riedel I, Czernobilsky B, Lifschitz-Mercer B, Roth LM, Wu X-R, Sun T-T, Moll R: Brenner tumors but not transitional cell carcinomas of the ovary show urothelial differentiation: Immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch 2001;438:181-191
74. Kaufmann O, Dietel M: Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 1999;36:8-16
75. Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G: Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046
76. Lugli A, Forster Y, Haas P, Nocito A, Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ, Sauter G: Calretinin expression in human normal and neoplastic tissues: A tissue microarray analysis on 5233 tissue samples. Hum Pathol 2003;34:994-1000
77. Ascoli V, Scalzo CC, Taccogna S, Nardi F: The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med 1995;119:1136-1140
78. Ordonez NG: Value of thrombomodulin immunostaining in the diagnosis of transitional cell carcinoma: A comparative study with carcinoembryonic antigen. Histopathology 1997;31:391-392
79. Skinnider B, Oliva E, Young RH, Amin MB: Expression of alpha-methylacyl-CoA racemace (P504S) in nephrogenic adenoma: A significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma. Am J Surg Pathol 2004;28:701-705
80. Gupta A, Wang HL, Policarpio-Nicolas ML, Tretiakova MS, Papavero V, Pins MR, Jiang Z, Humphrey PA, Cheng L, Yang XJ: Expression of alpha-methylacyl- coenzyme A racemase in nephrogenic adenoma. Am J Surg Pathol 2004;28:1224-1229
81. Cheng L, Montironi R, Bostwick DG: Villous adenoma of the urinary tract: A report of 23 cases, including 8 with co-existent adenocarcinoma. Am J Surg Pathol 1999;23:764-771
82. Donne C, Vidal M, Buttin X, Becerra P, Carvia R, Zuluaga A, Nogales FF: Mullerianosis of the urinary bladder: Clinical and immunohistochemical findings. Histopathology 1998;33:284-292
83. Ikegami H, Iwasaki H, Ohjimi Y, Takeuchi T, Arihoshi A, Kikuchi M: Sarcomatoid carcinoma of the urinary bladder: A clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol 2000;31:332-340
84. Martin SA, Sears DL, Sebo TJ, Lohse CM, Cheville JC: Smooth muscle neoplasms of the urinary bladder: A clinicopathologic comparison of leiomyoma and leiomyosarcoma. Am J Surg Pathol 2002;26:292-300
85. Iczkowski KA, Shanks JH, Gadaleanu V, Cheng L, Jones EC, Neumann R, Nascimento A, Bostwick DG: Inflammatory pseudotumor and sarcoma of urinary bladder: Differential diagnosis and outcome in thirty-eight spindle cell neoplasms. Mod Pathol 2001;14:1043-1051
86. Jones EC, Clement PB, Young RH: Inflammatory pseudotumor of the urinary bladder: A clinicopathological, immunohistochemical, ultrastructural, and flow cytometric study of 13 cases. Am J Surg Pathol 1993;17:264-274
87. Ro JY, El-Naggar AK, Amin MB, Sahin A, Ordonez NG, Ayala AG: Pseudosarcomatous fibromyxoid tumor of the urinary bladder and prostate: Immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases. Hum Pathol 1993;24:1203-1210
88. Tsuzuki T, Magi-Galluzzi C, Epstein JI: ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2004;28:1652-1654
89. Freeman A, Geddes N, Munson P, Joseph J, Ramani P, Sandison A, Fisher C, Parkinson MC: Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: A preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol 2004;17:765-771
90. Westra WH, Grenko RT, Epstein JI: Solitary fibrous tumor of the lower urogenital tract: A report of five cases involving the seminal vesicles, urinary bladder, and prostate. Hum Pathol 2000;31:63-68
91. Cheng L, Scheithauer BW, Leibovich BC, Ramnani DM, Cheville JC, Bostwick DG: Neurofibroma of the urinary bladder. Cancer 1999;86:505-513
92. Cheng L, Nascimento AG, Neumann RM, Nehra A, Cheville JC, Ramnani DM, Leibovich BC, Bostwick DG: Hemangioma of the urinary bladder. Cancer 1999;86:498-504
93. Pan C-C, Yu I-T, Yang A-H, Chiang H: Clear cell myomelanocytic tumor of the urinary bladder. Am J Surg Pathol 2003;27:689-692
94. Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y: p53 Immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38:691-699
95. Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z: Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 2003;199:323-328
96. Lu M, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C: Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002;8:171-179
97. Rotterud R, Berner A, Holm R, Skovlund E, Fossa D. p53, p21, and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int 2001;88:202-208
98. Jahnson S, Karlsson MG: Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 2000;89:619-629
99. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N: Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129-1136
100. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A, Trentini GP: Cyclin D1 expression in papillary superficial bladder cancer: Its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002;97:671-678
101. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Hastazeris K, Salmas M, Stefanaki S, Agnantis NJ: Expression patterns of cyclins D1, E, and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: Correlation with other cell-cycle-related proteins (Rb, p53, Ki-67, and PCNA) and clinicopathological features. Urol Int 2004;73:65-73
102. Shiraishi K, Eguchi S, Mohri J, Kamiryo Y: P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of the bladder. Anticancer Res 2003;23:3475-3478
103. Kim JH, Shariat SF, Kim I, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP: Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001;92:1475-1483
104. Tut V, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK: Cyclin D1 expression in transitional cell carcinoma of the bladder: Correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001;84:270-275
105. Wagner U, Seuss K, Luginbuhl T, Schmid U, Ackermann D, Zellweger T, Maurer R, Alund G, Knonagel H, Rist M, Jordan P, Moch H, Mihatsch MJ, Gasser TC, Sauter G: Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44-50
106. Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P: WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem 2000;8:285-292
107. Catto JW, Xinarianos G, Burton JL, Meuth M, Hamdy FC: Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatelite instability. Int J Cancer 2003;105:484-490
108. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopes C: Neovascularization is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol 2003;14:1419-1424
109. Hawke CK, Delahunt B, Davidson P: Microvessel density as a prognostic marker for transitional cell carcinoma of the bladder. Br J Urol 1998;81:585-590
110. Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004;22:1-6
111. Oka N, Yamamoto Y, Takahashi N, Nishitani M, Kanayama HO, Kagawa S: Expression of angiopoetin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 2005;95:660-663
112. Theodoropoulos VE, Lazaris A, Kastriotis I, Spiliadi C, Theodoropoulos G, Tsoukala V, Patsouris E, Sofras F: Evaluation of hypoxia-inducible factor 1 alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int 2005;95:425-431
113. Younes M, Juarez D, Lechago L, Lerner SP: Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 2001;21:575-578
114. Lebret T, Watson RW, Molinie V, O'Neill A, Gabriel C, Fitzpatrick JM, Botto H: Heat shock proteins HSP27, HSP60, HSP70, and HSP90: Expression in bladder carcinoma. Cancer 2003;98:970-977
115. Gontero P, Banisadr S, Frea B, Brausi M: Metastasis markers in bladder cancer: A review of the literature and clinical considerations. Eur Urol 2004;46:296-311
116. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA, Wheeler TM, Lerner SP: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165:1473-1479
117. Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, Hoznek A, Bastuji-Garin S, Abbou CC, Thiery JP, Radvanyi F, Chopin DK: Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000;83:209-214
118. Garcia del Muro X, Torregrosa A, Munoz J, Castellsague X, Condom E, Vigues F, Arance A, Fabra A, Germa JR: Prognostic value of the expression of E-cadherin and b-catenin in bladder cancer. Eur J Cancer 2000;36:357-362
119. Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M, Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int 2005;95:655-659
120. Gakiopoulou H, Nakapoulou L, Siatelis A, Mavrommatis I, Panayotopoulou EG, Tsirmpa I, Stravodimos C, Giannopoulos A: Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003;9:5573-5581
121. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM: HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89:1305-1309
122. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, Sayk F, Feller AC, Bohle A: HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 2002;102:514-518
123. Gandour-Edwards R, Lara PN, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ: Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009-1015
124. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM: Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: A study in Greek patients. Mod Pathol 1995;8:758-764
125. Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, Abbou CC, Chopin DK: Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: Therapeutic implications. Urol Oncol 2004;22:93-101
126. Karoui M, Hofmann-Radvanyi H, Zimmermann U, Couvelard A, Degott C, Faridoni-Laurens L, Ahomadegbe J-C, Gazzeri S, Brambilla E, Clerici T, Charbonnier P, Tresallet C, Mitry E, Penna C, Rougier P, Boileau C, Thiery J-P, Nordlinger B, Franc B, Radvanyi F: No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001;20:5059-5061
127. Sibley K, Stern P, Knowles MA: Frequency of fibroblast growth factor 3 mutations in sporadic tumours. Oncogene 2001;20:4416-4418
128. van Rhijn BG, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-251
129. Matsumoto M, Ohtsuki Y, Seike Y, Iseda N, Sasaki T, Okada Y, Kurabayashi A, Furihata M: Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 2004;12:967-971
130. Gomez-Roman JJ, Saenz P, Gonzales JC, Escuredo K, Santa Cruz S, Junquera C, Simon L, Martinez A, Banos JLG, Lopez-Brea M, Esparza C, Val-Bernal JF: Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulated the neoplastic cell growth. Clin Cancer Res 2005;11:459-465
131. Sweeney CJ, Marshall M, Barnard DS, Heilman D, Billings S, Cheng L, Marshall S, Yip-Schneider MT: Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 2002;26:238-244
132. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S: Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001;165:1468-1472
133. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer J, Woerner B, Snyder PW, Koki AT: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-5650
134. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser TC, Herberer M, Sauter G, Spagnoli GC: Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study. Int J Cancer 2002;100:702-705
135. Papsidero L, Croghan GA, Asirwatham J, Gaeta J, Abenoza P, Englander L, Valenzuela L: Immunohistochemical demonstration of prostate-specific antigen in metastases with the use of monoclonal antibody F5. Am J Pathol 1985;121:451-454
136. Loy TS, Quesenberry JT, Sharp SC: Distribution of CA 125 in adenocarcinomas: An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175-179
137. Brunnemann RB, Ro JY, Ordonez NG, Mooney J, El-Naggar AK, Ayala AG: Extrapleural solitary fibrous tumor: A clinicopathologic study of 24 cases. Mod Pathol 1999;12:1034-1042